In 2025, the US generic drug manufacturing sector has seen notable expansions and investments, driven primarily by new tariffs, policy initiatives to onshore production, and efforts to address drug shortages and supply chain vulnerabilities. These developments aim to reduce reliance … Continue reading Increase In Generic Drug Manufacturing Capacity Of US In 2025